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Health-related fitness and quality of life following steroid with- Patients presenting for renal transplantation are lim-
drawal in renal transplant recipients. ited in their exercise capacity [1–12]. Although exercise
Background. Exercise capacity increases significantly soon capacity improves dramatically soon after successful
after transplantation; however, over time it does not further
transplantation [7, 13], patients who remain inactive haveimprove and patients remain low compared to normal levels.
markedly reduced exercise capacity at 1 year posttrans-The limitations to exercise following transplantation have not
been identified, but may be related to immunosuppression ther- plant [14, 15]. Kempeneers et al [16] reported that exer-
apy regimens that include prednisone. cise capacity is limited following transplantation by skel-
Methods. We studied health-related fitness measures (car- etal muscle myopathy, which is not fully corrected with
diorespiratory fitness, muscle strength, and body composition)
exercise training. Although there are many possible fac-and quality of life in renal transplant recipients randomized
tors contributing to limitations to exercise in patientsinto two groups: those using standard maintenance immuno-
with end-stage renal disease (ESRD) treated with dial-suppression, including prednisone therapy (N 14); and those
undergoing rapid withdrawal of steroids using Simulect [in- ysis [4, 10, 11, 17, 18], cause for persistent limitation
terleukin-2 (IL-2) receptor inhibitor] (N  9). Testing was following transplant has not been clearly identified. The
done at 3 and 12 months following transplant and the 12-month effects of immunosuppression, specifically glucocorti-data were compared to 15 normal sedentary controls.
coids, on muscle function and structure is well docu-Results. Compared to those maintained on steroids, the ste-
mented by Horber et al [19, 20]. It is unclear whetherroid withdrawal group showed greater gains in VO2peak (P 
0.05) and quadriceps peak torque (P 0.05) and greater gains the absence of steroids from maintenance immunosup-
in the vitality score and the Physical Composite Scale on the pressive regimens improve exercise capacity, muscle struc-
SF-36 questionnaire (P  0.05). At 1 year, all patients had ture, or muscle function.
significantly lower exercise capacity compared to the sedentary
Glucocorticoids cause proximal muscle weakness andcontrols (P  0.01). No differences were observed in body
atrophy. Ultrastructural abnormalities in skeletal musclecomposition, with both patient groups increasing in body
weight (primarily body fat) over time. At 12 months, all patients include reduced myofibrillar mass, mitochondrial vol-
were not different in body fat percentage compared to the ume, and decreased capillary number. Lower extremities
sedentary controls. typically are the first affected, demonstrating the first
Conclusion. We conclude that prednisone is not the cause
signs of weakness during climbing stairs and rising fromfor increased body fat following transplantation; however, it
chairs. Quadriceps strength is markedly reduced in bothmay contribute to lower spontaneous improvements in exercise
kidney and heart transplant recipients [16, 20, 21] andcapacity possibly by limiting increases in muscle strength. The
low exercise capacity in all transplant recipients studied at 1 reported to be 80% [20] and 69% [22] of untrained sed-
year suggests a need for exercise training to optimize physical entary control subjects. The atrophy of skeletal muscle
functioning following transplant.
with administration of glucocorticoids is related to in-
creased amino acid efflux and decreased rates of protein
synthesis. Additionally, glucocorticoids may also reduceKey words: exercise capacity, health-related fitness, renal transplanta-
tion, prednisone withdrawal. mitchondrial respiration in skeletal muscle [23–25]. Re-
gardless of the mechanism, it is clear that the atrophy
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fitness following transplant. The availability of newer, ing as established by the American Heart Association
[26] or American College of Sports Medicine [27].more specific immunosuppression provides the opportu-
nity to withdraw patients from prednisone following
Prednisone Withdrawal Protocoltransplant and offers the promise of achieving normal
levels of fitness. A total of 36 transplant recipients and 15 sedentary
control subjects were recruited into the study. The immu-The purpose of this study is to compare health-related
fitness (cardiorespiratory fitness, muscle strength, and nosuppression protocol was as follows. All patients (in
both groups) received basliximab (Simulect, Novartisbody composition) and quality of life over the first year
following renal transplantation in patients with rapid elim- Pharmaceuticals, East Hanover, NJ, USA) (20 mg intra-
venously) on days 0 and 4, Cyclosporin (Neoral, No-ination of steroids with recipients managed with a standard
immunosuppression regimen that includes prednisone. vartis Pharmaceuticals) (4 to 5 mg/kg orally) twice daily
starting postoperative day 1 and mycophenolate mofetil
(Cellcept, Roche Laboratories, Nutley, NJ, USA) (1 g
METHODS
orally preoperatively, then 1.0 to 1.5 g orally twice daily
Subjects starting postoperative day 1). Prednisone was given to
all patients at the following doses postoperatively: day 0,Kidney transplant recipients were recruited from the
population of approximately 290 patients per year trans- 500 mg methylprednisolone (Solumedrol) intravenously;
day 1, 250 mg Solumedrol intravenously; and day 2, 125planted at the University of California, San Francisco
(UCSF). All patients were unsensitized recipients of first mg Solumedrol intravenously. Patients randomized into
rapid elimination of steroids were decreased to 30 mgcadaveric, living related, or living unrelated donor renal
transplants. Sedentary controls were recruited from the at day 4 and were withdrawn at day 5. Those randomized
into standard prednisone maintenance therapy were ta-hospital staff and the larger community. Recruitment
attempted to match controls to the patients for age and pered to 20 to 30 mg/day of prednisone over day 4 to
day 20. From day 21 to day 90, they were tapered inactivity (i.e., all were physically inactive).
Patients were a part of a larger study being conducted their final prednisone dose that ranged from 5 to 10 mg/
day. This was a standard taper of 5 mg decrease everyat UCSF studying the efficacy of steroid-free mainte-
nance immunosuppression regimens. This study random- other week with the final dose determined primarily by
body weight. Maintenance immunosuppression for bothly assigned patients to one of two groups: (1) induction
therapy with an interleukin-2 (IL-2) inhibitor (Simu- groups included standard CellCept dosing (2 to 3 g/day)
and Neoral to maintain trough levels 200 to 250 ng/mL.lect) and rapid elimination of prednisone versus (2)
induction therapy and maintenance immunosuppression,
Testingincluding prednisone (see Prednisone Withdrawal Pro-
tocol below). The investigators were blinded to the pred- Patients underwent baseline testing at 3 months post-
transplant with repeat testing at 12 months posttrans-nisone treatment group. The patients signed a separate
consent for this study, which was approved by the UCSF plant. The testing was all performed on a single visit
and included symptom-limited treadmill exercise testing,Committee on Human Research and the Advisory Com-
mittee for the UCSF General Clinical Research, where isokinetic muscle function testing, body composition
analysis, and completion of a quality-of-life question-the studies were completed.
Patients were recruited from the adult renal transplant naire. Muscle biopsies were also performed, the data of
which are presented elsewhere [28].population (i.e., 18 years of age). Patients were ex-
cluded from the rapid elimination of steroid study if they Cardiorespiratory exercise testing. Symptom-limited ex-
ercise testing was performed on a treadmill. Oxygen up-had (1) positive T-cell cross match or ABO incompatibil-
ity against the donor; (2) previous or multiple organ take (VO2) was determined using a computerized open-
circuit spirometry system (Quinton QMC, Bothell, WA,transplants; (3) evidence of transplant rejection; (4) in-
creased risk for graft rejection; or (5) a last panel reactive USA), which was calibrated against known gases prior
to each test. Expired respiratory gases were analyzed forantibody level greater than 30% at the time of trans-
plantation. Further exclusion criteria included (1) human volume, fractions of oxygen and carbon dioxide, and oxy-
gen uptake was calculated. Peak oxygen uptake (VO2peak)immunodeficiency virus (HIV) positivity; (2) active hep-
atitis; (3) history of malignancy; (4) history of myocardial is expressed in terms relative to body weight (mL O2/kg
body weight/minute). Age-predicted VO2peak was deter-infarction within six months prior to the study; or (5)
cardiac arrhythmias or other severe or unstable medical mined using formulas reported for sedentary normal in-
dividuals by Bruce, Kusumi and Hosmer [29]: VO2peakconditions. Additional exclusion criteria for the exercise
testing study included orthopedic or musculoskeletal dis- for males  57.8–0.445  age; and VO2peak for females 
42.3–0.356  age.orders that would prevent completion of the exercise
testing or any absolute contraindications to exercise test- The branching protocol [30] was used for testing,
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which established a comfortable walking speed, after inactive using the following sequence of questions: Do
you exercise regularly? If yes, what type(s) of exercisewhich the work intensity was increased by increasing
grade to achieve approximately 1 metabolic unit incre- do you do? How many times per week do you exercise?
How long do you exercise per session? How hard doments between stages. The work rate increased every 2
minutes until the subject was unable to continue (voli- you exert yourself during your exercise (rating 1 to 5).
This allowed us to classify patients into active or inactivetional fatigue) or until there was indication to discontinue
the test (i.e., electrocardiographic changes, inappropriate according to the Surgeon General’s Report Guidelines
[34]. The classification of active required cardiovascularblood pressure response) [27]. A 12-lead electrocardio-
gram was monitored continuously throughout the test, and exercise three or more times per week for at least 30
minutes per session at an intensity described as “some-blood pressure was auscultated at every stage. Ratings
of perceived exertion (subjective rating of effort) (RPE) what hard” or greater. All others were classified as inac-
tive.were measured at each stage on a 6 to 20 scale [31].
Muscle strength. Quadriceps muscle strength was mea-
Data analysissured using a computerized isokinetic muscle function
testing system (Biodex II, New York, NY, USA). The Descriptive statistics (means, standard deviations) were
calculated for all continuous variables. Frequencies wereright leg was attached to a dynamometer allowing for
isolation of the quadriceps muscle group. The patient generated for other variables. Repeated measures analy-
sis of variance with 1 within factor (time, baseline and 12performed maximal effort knee extensions (kicks) at a
controlled speed of 180 per second for 20 repetitions. months) and 1 between factor (group, standard therapy
versus steroid withdrawal) was used to determine differ-Variables measured for analysis were peak torque (the
highest torque developed during the set of repetitions ences between the two patient groups over the study
time. This analysis allows for testing of the main effectsmeasured in foot pounds) and peak torque per body
weight (%). of group and the main effects of time as well as the
interaction of group by time. The group by time interac-Body composition. Body composition was determined
using dual energy x-ray absorptiometry (DEXA) (Ho- tion indicates whether the change over time differs be-
tween the groups. Univariate analysis of variance waslogic QDR 4500, Bedford, MA, USA). The machine was
calibrated daily using known phantoms. The software used to compare the two patient groups at 12 months to
the control subjects. This analysis was performed usingfrom a full body scan determined bone mineral density
(g/cm2), lean body mass (g), and fat mass (g). Percent gender as a covariate since the control group had more
females than the patient groups. Statistical significancebody fat was calculated from the fat mass and total body
weight. was set at P  0.05.
Health-related quality of life. The Medical Outcomes
Short Form (SF-36) questionnaire was used to evaluate
RESULTS
self-reported domains of health status [32]. The SF-36
Subjectsis a 36-item questionnaire that includes eight compo-
nents of health-related quality of life: physical function- Since repeated measures analysis of variance only
allows for inclusion of those subjects who completeding (PF), role limitations due to physical health (RP),
body pain (BP), general health (GH), vitality (VT), so- both baseline and 12-month testing, 25 transplant recipi-
ents are included in the analysis (10 in the rapid elimina-cial functioning (SF), role limitations due to emotional
health (RE), and mental health (MH). These scales are tion of steroids group and 15 in the standard immunosup-
pression therapy, including prednisone). Reasons for lossscored from 0 to 100, with higher scores being more
positive (i.e., less pain, less limitation). Normalized of subjects at the 12-month testing included four lost to
follow-up, one transplant rejection, two with medicalscores representing overall physical functioning and
mental functioning are calculated from the individual contraindications to testing at 12 months (foot ulcer and
chronic hypotension), two with a change to prednisonescales and are presented as the physical composite scale
(PCS) and the mental composite scale (MCS). The PCS in the steroid elimination of steroid protocol, two who
refused repeat testing. Two diabetic patients were notincludes the dimensions of PF, RP, BP, GH, VT, and SF.
The MCS is composed of the RE and MH and includes included in the analysis. Fifteen sedentary control sub-
jects completed one testing session for comparative anal-elements of the GH, VT, and SF scales as well [33]. The
scaling of each of these component scores is around 50 ysis. The controls were apparently healthy, with no medi-
cal conditions and were not taking any medication. Allfor normal population values. Questionnaires were given
to patients following each testing session to be completed control subjects were sedentary (i.e., not participating in
any regular program of exercise).independently and returned by mail.
Activity participation. Activity levels were determined Demographics, laboratory values, and immunosup-
pression medications for those subjects who completedby self-report and subjects were classified as active or
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Table 3. Body composition (meanSD)Table 1. Demographics (meanSD)
Steroid Standard Sedentary Steroid Standard Sedentary
avoidance therapy controlsavoidance therapy controls
(N  9) (N  14) (N  15)
Height cm 173.37.9 172.611.3 168.38.9
Weight kgGender (m/f) % 6/3 (66/33%) 11/3 (78/22%) 6/9 (40/60%)
Age years 48.312.7 46.814.4 50.76.7 Baseline 77.511.1 78.414.4 71.911.2b
12 months 81.212.3a 81.514.9aEthnicy (Number) %
Caucasian 7 (78%) 7 (50%) 9 (60.0%) BMI
Baseline 26.04.5 27.14.9 25.43.7Hispanic 2 (22%) 3 (21.7%) 2 (13.3%)
African American 1 (7.1%) 1 (6.7%) 12 months 27.44.8 27.14.9
Total lean mass kgAsian/Pacific Islander 2 (14.3%) 3 (20%)
Other 1 (7.1%) Baseline 53.79.9 54.79.8 48.127.6
12 months 54.911.0 55.910.9Cause of renal failure
Glomerulonephropathy 1 (11.1%) 2 (14.3%) Total fat mass kg
Baseline 27.77.9 21.38.6 21.67.1bHypertension 2 (22.2%) 2 (14.3%)
IgA nephropathy 2 (22.2%) 1 (7.1%) 12 months 30.713.7a 24.29.6a
% FatPCKD — 3 (21.4%)
Hydronephrosis 1 (11.1%) — Baseline 27.77.9 28.49.5 29.77.4
12 months 30.77.6a 29.09.6aUnknown 3 (33.3%) 4 (28.6%)
a P  0.05 over time (from baseline to 12 months)PCKD is polycystic kidney disease.
b P  0.05 controls vs. all patients at 12 months
Table 2. Immunosuppression and laboratory values for patient
Table 4. Physiologic variables at peak exercise (meanSD)group (meanSD)
Steroid Standard SedentarySteroid Standard
avoidance therapy controlsavoidance therapy
Peak VO2 mL/kg/minImmunosuppression
Baseline 21.54.6 25.36.5 28.63.7bPrednisone mg/day
12 months 24.16.5a 23.786.0aBaseline — 13.23.5
% Age-predicted VO212 months — 6.92.5a
Baseline 66.67.9 72.615.0 96.817.8bCyclosporine mg/day
12 months 74.611.0a 66.27.9aBaseline 472.2198.6 491.7223.4
Peak heart rate12 months 322.2148.1a 312.5146.4a
Baseline 13926 14425 16813bMycophenolate mofetil mg/day
12 months 1412 13126Baseline 1583.3707.2 1545.1650.1
Peak RPE12 months 1333.3559.0 1145.5694.8
Baseline 18.51.0 17.41.8 17.51.9Laboratory values
12 months 17.80.9 17.12.9Creatinine mg/dL
Respiratory exchange ratioBaseline 1.440.41 1.270.41
Baseline 1.070.08 1.060.07 1.120.07b12 months 1.500.52 1.360.61
12 months 1.100.07 1.050.07Blood urea nitrogen mg/dL
Baseline 25.310.3 29.810.7 RPE is rating of perceived exertion.
12 months 26.77.9 25.510.3 a P  0.05 over time (from baseline to 12 months)
b P  0.05 controls vs. all patients at 12 monthsHematocrit %
Baseline 34.44.2 32.012.8
12 months 38.87.4a 40.26.4a
a P  0.01 compared to baseline
5.15; P 0.03) and percent fat (F1,20  28.33; P 0.0001)
(Table 3). There was no difference between the patient
groups in the increases in fat mass or percent fat over
both baseline and 12-month testing and for the sedentary time. At 1 year, both groups of patients had a greater
control group are shown in Tables 1 and 2. The patients fat mass than the controls regardless of steroid usage
were not on any medications that would affect the heart (P 0.05), even when controlling for gender differences
rate response to exercise (specifically  blockers). There between groups. The percent fat was, however, not dif-
were no differences in age among the three groups and ferent at 1 year between the patients and the controls.
no differences in laboratory measures of renal function There were no differences in lean body mass over time
between the two patient groups at either baseline or 12 or between the patient groups and controls at 12 months,
months. even when controlled for gender differences.
Body composition Cardiorespiratory fitness
All patients gained weight over the study time period. Physiologic data at peak exercise are shown in Table
The weight gained predominantly was fat, as indicated 4. There were no differences at baseline between the
patient groups in the VO2peak measurements. Patientsby a significant effect of time in total fat mass (F1,20 
Painter et al: Fitness after prednisone withdrawal 2313
Fig. 1. Changes in fitness measures from
baseline to 12 months. Symbols are () on
prednisone; () off prednisone. *P  0.01,
time by group interaction; **P  0.05, time
by group interaction.
Table 5. Isokinetic muscle test variables (meanSD)successfully maintained on steroid-free immunosuppres-
sion had significantly greater gains in VO2peak than the Steroid Standard Sedentary
avoidance therapy controlsstandard therapy group (time by group interaction: F1,20 
Peak torque (foot pounds)7.16; P 0.01). The standard therapy actually decreased
180/secondin their VO2peak levels (Fig. 1). Baseline 56.119.8 60.521.8 57.115.0
At 1 year posttransplant, all patients remained lower 12 months 61.823.6a 60.519.6
Peak torque/body weight %in both VO2peak and in percent of age predicted VO2peak
Baseline 32.58.8 35.913.8 39.112.1compared to the sedentary control subjects (Table 4).
12 months 34.311.3 34.812.5
All transplant recipients achieved a perceived exertion
a Time  group interaction; P  0.05rating (RPE)17 (which indicates a subjective maximal
effort), which was not different than the subjective ef-
forts of the controls. The respiratory exchange ratio a significant time by group interaction in this measure,
(RER) (a physiologic indicator of maximal effort) of indicating that those on standard therapy did not change
1.0 was also achieved by all patients. However, the over time, but the group maintained on the steroid-free
RER was significantly lower in all patients at 1 year regimen increased in muscle strength (F1,20  3.72; P 
compared to the controls (P  0.007) (Table 4), sug- 0.05) (Table 5) (Fig. 1). The values of peak torque/ body
gesting a muscle metabolic limitation to higher levels of weight were not different over time or between groups
exercise in the patients. over time. There was no difference in the peak torque
Patient heart rates at peak exercise at 1 year were or peak torque/body weight at 1 year between either of
significantly lower than the sedentary controls (Table 4). the patient groups and the sedentary control subjects,
Patients only achieved 75% to 78% of age predicted even when controlled for gender.
maximal heart rates, compared to 98% of age-predicted
Health-related quality of lifelevels for the controls. Patients were not on any medica-
tions that would affect heart rate response to exercise. The scores for the SF-36 questionnaire for the two
patient groups are found in Table 6. There were no
Isokinetic muscle function statistically significant differences between the two
There were no differences in baseline values for quad- groups in any of the scale scores at baseline. Statistically
riceps peak torque at a contraction speed of 180 per significant time by group interactions were found in the
second. There was a significant increase in this measure vitality score (F1,19  4.02; P 0.048) and in the Physical
Composite Scale (F1,19  3.77; P  0.05). This indicatesin all patients over time (F1,20 3.89; P 0.05). There was
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Table 6. SF-36 scale scores clinical outcomes and is thought to be another alternative
for immunosuppression therapy in unsensitized patientsSteroid Standard Sedentary
Scale score on SF-36 avoidance therapy controls [35, 36]. The irritating side effects and clinical conse-
Physical functioning quences of long-term steroid therapy, as well as the emer-
Baseline 82.117.3 68.318.8 95.06.5c gence of other more specific immunosuppression, have
12 months 89.317.6 69.423.1
led to increasing interest in the possibility of steroid-Role physical
Baseline 37.542.5 50.035.4 98.26.7c minimizing or steroid-free immunosuppression therapy.
12 months 75.040.0a 63.943.5a This study is the first to document the effects of steroid
Bodily pain
minimization on health-related fitness. Measures of fit-Baseline 64.420.6 71.921.8 91.813.9c
12 months 75.614.3 67.226.5 ness are important in that they are predictive of all-cause
General health mortality and cardiovascular mortality in the general
Baseline 64.420.6 70.020.3 80.713.1c
population [37]. Although no studies have linked fitness12 months 64.414.3 61.718.9
Vitality to outcomes in transplant recipients, optimization of
Baseline 50.027.7 69.814.6 65.422.9 functioning following transplantation is in the best inter-
12 months 64.422.8b 65.612.8b
est of patients and the transplant community. LimitationsSocial functioning
Baseline 78.121.9 73.621.1 97.37.2c to exercise have not been identified in transplant recipi-
12 months 84.417.4 68.025.1 ents; however, steroid therapy and the resulting muscle
Mental health
dysfunction has been suspected as one of the possibleBaseline 86.012.1 78.214.0 81.713.3
12 months 83.514.7 80.49.6 limiting factors [7, 16, 19, 20, 38].
Role emotional The weight gain following transplant in both patient
Baseline 66.739.8 77.737.3 92.819.3
groups confirms the cross-sectional data presented by12 months 91.723.6 77.737.3
Physical composite score Van Den Ham et al [39] who found no differences in
Baseline 42.08.6 42.97.5 55.452.9c body composition between groups of kidney transplant
12 months 48.48.7b 42.612.1b
recipients treated with 0, 5, or 10 mg per day of steroids.Mental composite score
Baseline 52.69.2 51.99.7 53.17.6 They also reported no relationship between the cumula-
12 months 56.03.4 52.39.1 tive dose of steroids and body composition in this group
a Effect of time (patients), P  0.05 of 77 renal transplant recipients. It is highly possible that
b Time  group (patients) interaction, P  0.05
lifestyle factors, specifically physical activity, determinec P  0.01 compared to all patients
body composition more than steroid doses. Van Den
Ham et al [39] found that leisure-time physical activity
a difference in the change over time between the two was positively related with percentage of lean body mass
groups, with the prednisone withdrawal group having and inversely related with fat mass. We reported that
greater gains and the prednisone-treated group actually physically active transplant games participants had sig-
deteriorating in some scale scores or showing no change nificantly lower body mass index (BMI) and percent
in others. Trends toward increases over time in the ste- body fat than did those who were physically inactive
roid-elimination group with no change or decreases in [14]. However, in an intent-to-treat exercise intervention
the standard therapy group were observed in the follow- over the first year posttransplant, we did not find any
ing scales: bodily pain, role limitations/physical, social differences in body composition between the exercise
functioning, and mental composite score. All patients intervention group (33% of whom were not regularly
increased in the role physical scale (effect of time, F1,19  active) and those in the usual care group [15]. However,
5.14; P  0.03); however, the increase in the steroid
secondary analysis comparing active versus inactive sub-
minimization group was much greater than that of the
jects (regardless of randomization groups) showed a sig-standard therapy group. The variation in the scores was
nificant trend toward lower BMI and percent fat in thehigh, thus the time by group interaction was not signifi-
active subjects. There was no dietary intervention in thatcant.
study and caloric intake was not different between theAt 12 months posttransplant, the patients had signifi-
groups.cantly lower scores on all the physical scales, including
This study is limited by the small numbers; however,the Physical Composite Scale, compared to the sedentary
the observations of statistically significant findings innormal controls (P  0.003). The patients did not differ
many of the measurements would not be expected infrom the controls in any of the mental scale scores except
small numbers. Thus, we think that the fact that statisticalfor social functioning (P  0.001) (Table 6).
significance was observed in repeated measures analysis
of variance was particularly impressive and represent
DISCUSSION real difference in exercise responses over the study time
between the two groups. We observed similar decre-The use of Simulect induction following renal trans-
plantation has been reported to have no detrimental ments in functioning in usual care group (treated with
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prednisone) over the first year posttransplant in another minants of VO2 are actually measured in this patient
group, there is no way to determine the relative contribu-study that included a larger number of subjects [15].
tions of cardiac output and peripheral oxygen utilization.The greater increases in peak VO2peak in the patients
Measurement of health-related quality of life is diffi-maintained on the steroid-free regimen suggests that,
cult, and often the variation in the scale scores necessi-following renal transplant, there is a greater spontaneous
tates large sample sizes to determine differences betweenincrease in functioning in those not on steroid therapy.
groups. Thus, the striking trends with statistical signifi-The repeated measures analysis of variance is an analysis
cance achieved in changes in the vitality score and theof change over time between the two groups. Although
overall Physical Composite Scale are impressive, consid-there was a trend (NS) for the prednisone withdrawal
ering the small numbers of subjects in this study. Thegroup to have lower values at baseline, the trend of those
trends of the physical function scale, the bodily pain,maintained on prednisone to deterioration in function
and the significant time by group interactions in the vital-over 1 year posttransplant is similar to that reported
ity and Physical Composite Scale parallel the physiologicpreviously in a larger study [15]. Patients maintained on
measurements of VO2peak and muscle strength (i.e., im-steroids showed a similar trend toward deterioration in
proved scores in the steroid avoidance group and eitherfunctioning over the first year to what we reported in
no change or decline in the standard therapy group).the usual care group of the exercise intervention trial
Lack of energy is a common complaint in transplant[15]. In that study, the VO2peak at 1 year was significantly
recipients. It may be possible that this overall lack ofhigher in the exercise group compared to the usual care
energy is due to prednisone therapy. Many more subjectsgroup, which had VO2peak values similar to high-function-
are required to confirm the effects of steroid minimiza-ing dialysis patients. This was also reported in our cross-
tion on quality of life; however, it appears in this prelimi-sectional analysis of active versus inactive transplant
nary study that overall quality of life is improved withgames participants [14]. There was no exercise interven-
steroid elimination.tion or exercise recommendations given to any subject
Although there were significant gains in cardiorespira-in the current study. Only two subjects (both in the
tory fitness and muscle strength in those patients not onstandard therapy group) reported regular participation
prednisone, it should be pointed out that all the patientsin physical activity.
remained low in VO2peak compared to the sedentary nor-The greater gains in VO2peak could be related to an
mal controls. The sedentary normal controls achievedimprovement in muscle functioning, as evidenced by the
96%  18% of their age-predicted maximal capacity,increased quadriceps muscle strength gains in the steroid
compared to only 67% in the patients. Thus, althoughavoidance group. Shephard et al [40] reports that lower
significantly greater gains were observed in those notextremity muscle mass is a determinant of external work
taking prednisone, all patients remain low in physicalperformed, thus determining VO2peak. Although our pa-
functioning at 1 year posttransplant. Exercise trainingtient group as a whole did not have lower lean mass
is thus warranted for this patient group for optimizingcompared to the control group, there were more males
functioning following transplant. Given the greater gainsin the patient group than the control group. However,
in patients not on prednisone (and actual deteriorationwhen the comparison with the normals was controlled
in those in the standard care), it is possible that thosefor gender, there was no difference in lean body mass
patients not taking prednisone will be able to achievebetween the patients and the controls. At the 1-year
higher levels of cardiorespiratory fitness and muscletesting time, the patients not on prednisone in this study
strength with exercise training than those remaining onhad significantly larger muscle fiber size (type IIX) than
prednisone.those on prednisone [28] and showed ultrastructural dif-
ferences that would suggest facilitated muscle contrac-
CONCLUSIONtion and oxygen utilization. It is possible that the micro-
scopic and ultrastructural changes did not show up in Withdrawal of steroid therapy following renal trans-
the total lean mass measurements, but could contribute plantation results in greater gains in the cardiorespira-
to the differences observed in muscle strength gains and tory fitness, and muscle strength. It has, however, had
VO2peak. no effect on body composition. Lifestyle interventions
Exercise capacity could also be limited by a blunted such as exercise training and dietary modification, which
heart rate response to exercise, which is typically seen are guidelines for reduction of cardiovascular risk, are
in patients with ESRD treated with dialysis [3, 4, 8, 17]. necessary for optimizing health-related fitness following
This blunted heart rate response observed in both patient renal transplantation.
groups in this study would limit maximal cardiac output,
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